0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Dermatology Patient Page |

Morphea (Localized Scleroderma) FREE

Nicole M. Fett, MD
JAMA Dermatol. 2013;149(9):1124. doi:10.1001/jamadermatol.2013.5079.
Text Size: A A A
Published online

Morphea is an autoimmune disease that causes sclerosis, or scarlike, changes to the skin.

Autoimmune diseases occur when the immune system, which normally protects us from bacteria, viruses, and fungi, mistakenly attacks a person’s own body. Morphea lesions have 5 main presentations: (1) circumscribed (few circles on the trunk or limbs); (2) generalized (many circles on the trunk and limbs); (3) linear (lines of involvement on the limbs or head); (4) mixed (combination of circumscribed and linear or generalized and linear); and (5) pansclerotic (involvement of all of the skin). Morphea is usually limited to the skin, but it may extend deeper to involve muscle or bone. Morphea may also involve the inside of the mouth, the genitals, and the eyes. Morphea often first occurs in childhood or middle adulthood. Treatment decreases the risk of forming new lesions and the expansion of lesions. There is currently no cure for morphea.

Morphea is usually asymptomatic, with occasional itch and rarely pain. Morphea usually begins as a red or purple area of skin that then becomes thickened and white. The thick white areas usually thin out over time and turn brown. Once a lesion has formed, it is unlikely to completely go away. In children, linear morphea on the arms and legs can affect the underlying bone and interfere with bone growth. Linear morphea on the head (also called en coup de sabre) may extend inwards to the brain and cause seizures. If morphea crosses a joint, the thickening may limit joint movement. Morphea tends to have a waxing and waning course.

Morphea is diagnosed based on findings of skin examination and skin biopsy. Patients with morphea do not have Raynaud phenomenon (fingers turning red, white, and blue with cold exposure), redness and swelling of both hands (red puffy hands), changes in the blood vessels along the nail edge (nailfold capillary changes), or tightening of the skin of the fingers (sclerodactyly). Patients who have these findings are likely to have systemic sclerosis, also called scleroderma. Systemic sclerosis and morphea are different diseases. Patients with morphea are not at increased risk of developing systemic sclerosis.

Treatments help to control itch and decrease the growth and formation of new lesions. The treatment will depend on morphea type. Generally, creams and ointments are given to patients with circumscribed morphea or linear morphea that involves just the skin. Generalized morphea, or morphea that involves the muscle and bone, is usually treated with phototherapy (regular exposure to UV light in a special machine) or a combination of oral steroids and methotrexate (medications that suppress the immune system).

Box Section Ref ID

For More Information

To find this and previous JAMA Dermatology Patient Pages, go to the Patient Page link on JAMA Dermatology’s website at jamadermatology.com.

Section Editor: Misha A. Rosenbach, MD
The JAMA Dermatology Patient Page is a public service of JAMA Dermatology. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA Dermatology suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 312/464-0776.

Conflict of Interest Disclosures: None reported.

Sources: Fett N. Clin Dermatol. 2013;31(4):432-437.

Fett N, Werth VP. J Am Acad Dermatol. 2011;64(2):231-242.

Fett N, Werth VP. J Am Acad Dermatol. 2011;64(2):217-228.

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Health-Related Quality of Life in Morphea. Br J Dermatol Published online Dec 6, 2014.;